Story
Coca-Cola System Pledges $10 Billion for US Infrastructure by 2030
Summary
The Coca-Cola Company, along with its bottling partners, has announced a five-year plan to invest $10 billion in its U.S. infrastructure from 2026 through 2030.
The Coca-Cola Company (NYSE: KO) announced on Tuesday its plan to invest $10 billion in U.S. infrastructure between 2026 and 2030. The significant financial commitment is a system-wide initiative that includes spending by the company and its network of bottling partners.
Investment Details
According to a statement, the planned spending encompasses projects that have been previously announced in states including California, Colorado, Alabama, and New York. The $10 billion figure represents a collective effort across the entire Coca-Cola system, not solely the company's direct capital expenditure.
In an interview with Fortune, CFO John Murphy clarified that the investment includes contributions from its bottling partners. For context, Coca-Cola had previously forecast its own capital expenditure for the current fiscal year to be approximately $2.2 billion in a July update.
Economic Impact Study
AdThe announcement coincided with the release of an independently commissioned study highlighting the system's economic contributions to the U.S. This is the second such study undertaken by the beverage giant, with the first published in September 2023.
Key findings from the report for a single year include:
- A contribution of $85 billion to the U.S. gross domestic product (GDP).
- Support for nearly 1 million jobs across the country.
- Approximately $37 billion spent with U.S.-based suppliers.
- A combined $177 million in community contributions from the company, its Coca-Cola Foundation, and the Coca-Cola Scholars Foundation.
Read next
More on Stocks
BOJ Rate Hike Nears, Pitting Japanese Financials Against Exporters
The Bank of Japan is widely expected to raise its key interest rate to a 31-year high this week, a move that is creating a sharp divide in the stock market between beneficiaries like banks and sectors facing pressure, such as exporters.
Genscript Biotech Stock Surges Over 16% on Eli Lilly AI Partnership
Shares in the Hong Kong-listed biotech firm rallied after announcing a collaboration with Eli Lilly's AI-powered drug discovery platform, a move supported by a recent capital raise focused on AI infrastructure.
Volkswagen's Seat Brand Faces Discontinuation Amid Chinese EV Pressure
Volkswagen is reportedly set to phase out its historic Spanish brand, Seat, as part of a major restructuring to combat rising competition from Chinese automakers and focus investment on its profitable, all-electric Cupra marque.
Hong Kong Biotech Sector Shows Stark Divide as Biocytogen, Genscript Post Major Gains
A small group of companies, led by Biocytogen Pharmaceuticals and Genscript Biotech, have delivered substantial one-year returns, highlighting a sharp performance gap within Hong Kong's 52-stock biotech universe where most firms remain unprofitable.